ISO 27001 Certificate
SOC 1 Type I Certificate
SOC 2 Type II Certificate
PCI DSS
HIPAA
RGPD
Internal validation & live display
Multiple badges & continuous verification
Faster underwriting decisions
ISOSOC2 Type 1SOC2 Type 2PCI DSSHIPAAGDPR

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2025, Grifols was named one of TIME’s ‘World’s Best Companies’ for the third year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best World Employers 2025," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Grifols A.I CyberSecurity Scoring

Grifols

Company Details

Linkedin ID:

grifols

Employees number:

12,388

Number of followers:

285,293

NAICS:

3254

Industry Type:

Pharmaceutical Manufacturing

Homepage:

linktr.ee

IP Addresses:

151

Company ID:

GRI_7337752

Scan Status:

Completed

AI scoreGrifols Risk Score (AI oriented)

Between 750 and 799

https://images.rankiteo.com/companyimages/grifols.jpeg
Grifols Pharmaceutical Manufacturing
Updated:
  • Powered by our proprietary A.I cyber incident model
  • Insurance preferes TPRM score to calculate premium
globalscoreGrifols Global Score (TPRM)

XXXX

https://images.rankiteo.com/companyimages/grifols.jpeg
Grifols Pharmaceutical Manufacturing
  • Instant access to detailed risk factors
  • Benchmark vs. industry & size peers
  • Vulnerabilities
  • Findings

Grifols Company CyberSecurity News & History

Past Incidents
0
Attack Types
0
No data available
Ailogo

Grifols Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

🔒
Incident Predictions locked
Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

🔒
A.I. Risk Score Predictions locked
Access Monitoring Plan
statics

Underwriter Stats for Grifols

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Grifols in 2025.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Grifols in 2025.

Incident Types Grifols vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Grifols in 2025.

Incident History — Grifols (X = Date, Y = Severity)

Grifols cyber incidents detection timeline including parent company and subsidiaries

Grifols Company Subsidiaries

SubsidiaryImage

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2025, Grifols was named one of TIME’s ‘World’s Best Companies’ for the third year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best World Employers 2025," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Loading...
similarCompanies

Grifols Similar Companies

EMS is the leading pharmaceutical company in Brazil. Established since 45 years and with 100% national capital, the company has two industrial plants strategically placed in São Bernardo do Campo and Hortolândia, in the state of São Paulo. With a work based on daring, simplicity, excellence and res

Cipla

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purp

Zoetis

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio an

Viatris

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage

Catalent

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier li

Novartis

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out mor

Sanofi

We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing t

SUN PHARMA

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread acro

AbbVie

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye ca

newsone

Grifols CyberSecurity News

May 24, 2024 07:00 AM
Cencora data breach exposes patient data at top pharma firms

The Cencora breach affected some of the most prominent Big Pharma firms, including Novartis, Bayer, AbbVie, Regeneron, Genentech and Incyte.

faq

Frequently Asked Questions

Explore insights on cybersecurity incidents, risk posture, and Rankiteo's assessments.

Grifols CyberSecurity History Information

Official Website of Grifols

The official website of Grifols is https://linktr.ee/Grifols.

Grifols’s AI-Generated Cybersecurity Score

According to Rankiteo, Grifols’s AI-generated cybersecurity score is 776, reflecting their Fair security posture.

How many security badges does Grifols’ have ?

According to Rankiteo, Grifols currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Does Grifols have SOC 2 Type 1 certification ?

According to Rankiteo, Grifols is not certified under SOC 2 Type 1.

Does Grifols have SOC 2 Type 2 certification ?

According to Rankiteo, Grifols does not hold a SOC 2 Type 2 certification.

Does Grifols comply with GDPR ?

According to Rankiteo, Grifols is not listed as GDPR compliant.

Does Grifols have PCI DSS certification ?

According to Rankiteo, Grifols does not currently maintain PCI DSS compliance.

Does Grifols comply with HIPAA ?

According to Rankiteo, Grifols is not compliant with HIPAA regulations.

Does Grifols have ISO 27001 certification ?

According to Rankiteo,Grifols is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Industry Classification of Grifols

Grifols operates primarily in the Pharmaceutical Manufacturing industry.

Number of Employees at Grifols

Grifols employs approximately 12,388 people worldwide.

Subsidiaries Owned by Grifols

Grifols presently has no subsidiaries across any sectors.

Grifols’s LinkedIn Followers

Grifols’s official LinkedIn profile has approximately 285,293 followers.

NAICS Classification of Grifols

Grifols is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Grifols’s Presence on Crunchbase

No, Grifols does not have a profile on Crunchbase.

Grifols’s Presence on LinkedIn

Yes, Grifols maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/grifols.

Cybersecurity Incidents Involving Grifols

As of December 22, 2025, Rankiteo reports that Grifols has not experienced any cybersecurity incidents.

Number of Peer and Competitor Companies

Grifols has an estimated 5,459 peer or competitor companies worldwide.

Grifols CyberSecurity History Information

How many cyber incidents has Grifols faced ?

Total Incidents: According to Rankiteo, Grifols has faced 0 incidents in the past.

What types of cybersecurity incidents have occurred at Grifols ?

Incident Types: The types of cybersecurity incidents that have occurred include .

Incident Details

What are the most common types of attacks the company has faced ?

Additional Questions

cve

Latest Global CVEs (Not Company-Specific)

Description

A vulnerability has been found in SeaCMS up to 13.3. The affected element is an unknown function of the file js/player/dmplayer/dmku/class/mysqli.class.php. Such manipulation of the argument page/limit leads to sql injection. The attack can be executed remotely. The exploit has been disclosed to the public and may be used.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in HappyDevs TempTool allows Stored XSS.This issue affects TempTool: from n/a through 1.3.1.

Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in Tormorten WP Microdata allows Stored XSS.This issue affects WP Microdata: from n/a through 1.0.

Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
Description

Exposure of Sensitive System Information to an Unauthorized Control Sphere vulnerability in HappyDevs TempTool allows Retrieve Embedded Sensitive Data.This issue affects TempTool: from n/a through 1.3.1.

Risk Information
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
Description

A vulnerability has been found in Tenda FH1201 1.2.0.14(408). Affected is the function sprintf of the file /goform/SetIpBind. Such manipulation of the argument page leads to stack-based buffer overflow. The attack may be performed from remote. The exploit has been disclosed to the public and may be used.

Risk Information
cvss2
Base: 9.0
Severity: LOW
AV:N/AC:L/Au:S/C:C/I:C/A:C
cvss3
Base: 8.8
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
cvss4
Base: 7.4
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Access Data Using Our API

SubsidiaryImage

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?linkedin_id=grifols' -H 'apikey: YOUR_API_KEY_HERE'

What Do We Measure ?

revertimgrevertimgrevertimgrevertimg
Incident
revertimgrevertimgrevertimgrevertimg
Finding
revertimgrevertimgrevertimgrevertimg
Grade
revertimgrevertimgrevertimgrevertimg
Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network Security

Identify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)

Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)

Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat Intelligence

Leverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Top LeftTop RightBottom LeftBottom Right
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.
Users Love Us Badge